Valuation: Keros Therapeutics, Inc.

Market Cap 22Cr 19Cr 17Cr 16Cr 30Cr 2.08TCr 30Cr 205.59Cr 80Cr 1.04TCr 82Cr 80Cr 3.45TCr P/E 2026 *
-2.01x
P/E 2027 * -1.74x
Enterprise Value 22Cr 19Cr 17Cr 16Cr 30Cr 2.08TCr 30Cr 205.59Cr 80Cr 1.04TCr 82Cr 80Cr 3.45TCr EV / Sales 2026 *
13.3x
EV / Sales 2027 * 17.2x
Free-Float
46.47%
Yield 2026 *
-
Yield 2027 * -
1 day-0.50%
1 week+7.82%
Current month+8.14%
1 month+3.03%
3 months-2.94%
6 months-30.68%
Current year-46.51%
1 week 10
Extreme 10
11.17
1 month 9.69
Extreme 9.69
11.43
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 01/12/2015
Director of Finance/CFO 55 03/08/2026
Chief Tech/Sci/R&D Officer 53 01/06/2019
Director TitleAgeSince
Chairman 70 01/07/2024
Director/Board Member 63 01/04/2016
Director/Board Member 50 01/03/2020
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Buy

Chairman

1,000 0.0051%
04/08/26 Other

Chief Financial Officer

1,17,468 0.5935%
15/07/26 Buy

Chairman

1,000 0.0051%
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%+7.82%-28.21%-69.43% 22Cr
-3.00%+0.33%+77.39%+109.41% 7.4TCr
+1.90%+23.53%+56.60%+97.76% 6.47TCr
+0.97%+2.34%-4.49%+475.64% 2.73TCr
+3.06%+23.12%+3.47%-2.48% 2.79TCr
+2.74%+11.55%+66.56%+27.34% 2.6TCr
+0.47%+6.12%+36.66%-13.79% 2TCr
+1.82%-3.11%+245.72%+423.83% 1.78TCr
+0.94%+2.38%+24.83%+552.12% 1.62TCr
+0.81%+5.95%+40.25%+154.05% 1.33TCr
Average +0.94%+5.82%+51.88%+175.45% 2.87TCr
Weighted average by Cap. +0.55%+6.66%+59.63%+161.25%

Financials

2026 *2027 *
Net sales 1.64Cr 1.4Cr 1.31Cr 1.2Cr 2.25Cr 156.64Cr 2.28Cr 16Cr 6.05Cr 79Cr 6.15Cr 6.01Cr 260.26Cr 1.26Cr 1.08Cr 1.01Cr 92.7L 1.74Cr 120.89Cr 1.76Cr 12Cr 4.67Cr 61Cr 4.74Cr 4.64Cr 200.87Cr
Net income -11Cr -9.29Cr -8.69Cr -7.96Cr -15Cr -1.04TCr -15Cr -102.68Cr -40Cr -521.19Cr -41Cr -40Cr -1.72TCr -15Cr -13Cr -12Cr -11Cr -20Cr -1.41TCr -21Cr -139.3Cr -54Cr -707.03Cr -55Cr -54Cr -2.34TCr
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
92
Date Price Change Volume
21/26/21 $10.90 -0.50% 71,363
20/26/20 $10.95 -1.35% 2,03,072
19/26/19 $11.10 +4.62% 1,52,154
18/26/18 $10.61 +1.24% 2,56,149
17/26/17 $10.48 +3.76% 2,21,513
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
10.95USD
Average target price
19.83USD
Spread / Average Target
+81.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock